Author: Weng, Dong; Yin, Zhao-Fang; Chen, Shan-Shan; He, Xian; Li, Nan; Chen, Tao; Qiu, Hui; Zhao, Meng-Meng; Wu, Qin; Zhou, Nian-Yu; Lu, Li-Qin; Tang, Dan-Li; Song, Jia-Cui; Li, Hui-Ping
Title: Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody Cord-id: 3rew11a5 Document date: 2021_7_5
ID: 3rew11a5
Snippet: Glucocorticoid (GC) hormone has been commonly used to treat systemic inflammation and immune disorders. However, the side effects associated with long-term use of high-dose GC hormone limit its clinical application seriously. GC hormone that can specifically target the lung might decrease the effective dosage and thus reduce GC-associated side effects. In this study, we successfully prepared human lung-targeting liposomal methylprednisolone crosslinked with nanobody (MPS-NSSLs-SPANb). Our findin
Document: Glucocorticoid (GC) hormone has been commonly used to treat systemic inflammation and immune disorders. However, the side effects associated with long-term use of high-dose GC hormone limit its clinical application seriously. GC hormone that can specifically target the lung might decrease the effective dosage and thus reduce GC-associated side effects. In this study, we successfully prepared human lung-targeting liposomal methylprednisolone crosslinked with nanobody (MPS-NSSLs-SPANb). Our findings indicate that MPS-NSSLs-SPANb may reduce the effective therapeutic dosage of MPS, achieve better efficacy, and reduce GC-associated side effects. In addition, MPS-NSSLs-SPANb showed higher efficacy and lower toxicity than conventional MPS.
Search related documents:
Co phrase search for related documents- abundant pulmonary expression and acute respiratory syndrome: 1
- acute respiratory syndrome and log rank test compare: 1
Co phrase search for related documents, hyperlinks ordered by date